Esperion Therapeutics Inc (NASDAQ:ESPR): Positive Stock Sentiment

September 8, 2018 - By Robert Shackelford

Sentiment for Esperion Therapeutics Inc (NASDAQ:ESPR)

Esperion Therapeutics Inc (NASDAQ:ESPR) institutional sentiment increased to 1.5 in 2018 Q1. Its up 0.17, from 1.33 in 2017Q4. The ratio is positive, as 90 funds opened new or increased equity positions, while 60 decreased and sold their holdings in Esperion Therapeutics Inc. The funds in our partner’s database now own: 24.56 million shares, up from 22.69 million shares in 2017Q4. Also, the number of funds holding Esperion Therapeutics Inc in their top 10 equity positions decreased from 6 to 4 for a decrease of 2. Sold All: 14 Reduced: 46 Increased: 54 New Position: 36.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $1.35 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

The stock increased 0.76% or $0.38 during the last trading session, reaching $50.18. About 344,196 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 12.80% since September 8, 2017 and is uptrending. It has outperformed by 0.23% the S&P500.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on November, 6. They expect $-1.60 EPS, up 13.98 % or $0.26 from last year’s $-1.86 per share. After $-1.71 actual EPS reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -6.43 % EPS growth.

Meditor Group Ltd holds 29.46% of its portfolio in Esperion Therapeutics, Inc. for 2.59 million shares. Bb Biotech Ag owns 2.41 million shares or 4.82% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 4.76% invested in the company for 100,000 shares. The Sweden-based Rhenman & Partners Asset Management Ab has invested 2.18% in the stock. Partner Fund Management L.P., a California-based fund reported 1.13 million shares.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Ratings analysis reveals 55% of Esperion’s analysts are positive. Out of 11 Wall Street analysts rating Esperion, 6 give it “Buy”, 3 “Sell” rating, while 2 recommend “Hold”. The lowest target is $4100 while the high is $15300. The stock’s average target of $88.30 is 75.97% above today’s ($50.18) share price. ESPR was included in 12 notes of analysts from March 19, 2018. The stock has “Buy” rating by Citigroup on Friday, August 17. As per Friday, May 4, the company rating was maintained by Credit Suisse. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Underweight” rating given on Thursday, May 3 by JP Morgan. The company was maintained on Tuesday, March 27 by Chardan Capital Markets. The firm earned “Sell” rating on Thursday, May 3 by J.P. Morgan. Cowen & Co maintained it with “Buy” rating and $9500 target in Tuesday, March 27 report. The firm earned “Buy” rating on Thursday, May 3 by Deutsche Bank. The rating was maintained by JMP Securities on Wednesday, May 2 with “Buy”. The rating was downgraded by Northland Capital on Wednesday, July 11 to “Market Perform”. On Thursday, April 19 the stock rating was maintained by Northland Capital with “Buy”.

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: Nasdaq.com which released: “Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of …” on August 25, 2018, also Fool.com with their article: “3 Biotech Stocks That Could Soar in September” published on September 02, 2018, Nasdaq.com published: “Market Trends Toward New Normal in Esperion Therapeutics, Oxford Immunotec Global, Limoneira, R1 RCM …” on August 20, 2018. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on August 17, 2018 as well as Nasdaq.com‘s news article titled: “Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” with publication date: August 10, 2018.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.